Canada - English - Health Canada

general nutrition canada inc. - zinc (zinc gluconate) - tablet - 10mg - zinc (zinc gluconate) 10mg - minerals

United States - English - NLM (National Library of Medicine)

hospira, inc. - zinc chloride (unii: 86q357l16b) (zinc cation - unii:13s1s8sf37) - zinc cation 1 mg in 1 ml - zinc 1 mg/ml (zinc chloride injection, usp) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms. none known. none known.

Canada - English - Health Canada

general nutrition canada inc. - ascorbic acid (ascorbic acid, sodium ascorbate); zinc (zinc oxide, zinc gluconate) - lozenge - 60mg; 10mg - ascorbic acid (ascorbic acid, sodium ascorbate) 60mg; zinc (zinc oxide, zinc gluconate) 10mg - vitamins & minerals

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6)] risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate.  the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc.  parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration (2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients.  in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [ see warnings and precautions ( 5.6) ]. risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration ( 2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions ( 5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

Canada - English - Health Canada

avir pharma inc. - sincalide - powder for solution - 5mcg - sincalide 5mcg - gallbladder function

Canada - English - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 1mg - zinc (zinc sulfate) 1mg

Canada - English - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 5mg - zinc (zinc sulfate) 5mg

Canada - English - Health Canada

general nutrition canada inc. - zinc (zinc citrate, zinc hvp chelate); potassium (potassium citrate); manganese (manganese citrate, manganese hvp chelate); molybdenum (molybdenum hvp chelate); selenium (selenium hvp chelate); chromium (chromium hvp chelate); choline bitartrate; inositol; biotin; retinol palmitate; beta-carotene (provitamin a); d-alpha tocopheryl acid succinate; ascorbic acid (calcium ascorbate); vitamin d3; thiamine mononitrate; vitamin b2; nicotinic acid; nicotinamide; pyridoxine hydrochloride; vitamin b12; d-pantothenic acid (calcium d-pantothenate); folic acid; iodine (kelp); calcium (calcium phosphate (dibasic), calcium citrate, calcium hvp chelate); magnesium (magnesium citrate, magnesium hvp chelate) - tablet (extended-release) - 7.5mg; 5mg; 3.05mg; 25mcg; 5mcg; 5mcg; 50mg; 50mcg; 50mcg; 3500unit; 1500unit; 100unit; 150mg; 200unit; 50mg; 50mg; 15mg; 35mg; 50mg; 50mcg; 50mg; .2mg; .025mg; 62.5mg; 25mg - zinc (zinc citrate, zinc hvp chelate) 7.5mg; potassium (potassium citrate) 5mg; manganese (manganese citrate, manganese hvp chelate) 3.05mg; molybdenum (molybdenum hvp chelate) 25mcg; selenium (selenium hvp chelate) 5mcg; chromium (chromium hvp chelate) 5mcg; choline bitartrate 50mg; inositol 50mcg; biotin 50mcg; retinol palmitate 3500unit; beta-carotene (provitamin a) 1500unit; d-alpha tocopheryl acid succinate 100unit; ascorbic acid (calcium ascorbate) 150mg; vitamin d3 200unit; thiamine mononitrate 50mg; vitamin b2 50mg; nicotinic acid 15mg; nicotinamide 35mg; pyridoxine hydrochloride 50mg; vitamin b12 50mcg; d-pantothenic acid (calcium d-pantothenate) 50mg; folic acid .2mg; iodine (kelp) .025mg; calcium (calcium phosphate (dibasic), calcium citrate, calcium hvp chelate) 62.5mg; magnesium (magnesium citrate, magnesium hvp chelate) 25mg - vitamins & minerals

Australia - English - Department of Health (Therapeutic Goods Administration)

nutrition care pharmaceuticals pty ltd - curcumin,echinacea angustifolia,magnesium amino acid chelate,manganese amino acid chelate,olea europaea,pyridoxine hydrochloride,retinol palmitate,zinc amino acid chelate -